Funding for this research was provided by:
Received: 4 June 2021
Accepted: 30 September 2021
First Online: 30 October 2021
: The MG0002 clinical study and the MG Symptoms PRO development study were performed in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Guidance for Good Clinical Practice. Study protocol (appendix), amendments, and patient-informed consent were reviewed by national, regional, or independent ethics committees or institutional review boards. Written informed consent was obtained from all patients.
: Not applicable.
: The copyright to the MG Symptoms PRO is owned by UCB Biopharma SRL, Belgium.
: SCl, AR and SCa are employees of Modus Outcomes, which received payment from UCB to conduct this research. HK is principal investigator of the Rare Disease Clinical Research Network (U54 NS115054); a consultant for Alnylam Pharmaceuticals, Caballata Bio, Roche, and UCB Pharma; and is CEO and CMO of ARC Biotechnology, LLC, based on US Patent 8961981. ACM and TM are employees and shareholders of UCB Pharma.